In a recent study by Fotios Barkas et al., the integration of genetic factors (monogenic risk factors and polygenic predisposition to ASCVD), imaging techniques (CAC, carotid magnetic resonance, and femoral ultrasound [US]), and biomarkers (Apolipoprotein-B (ApoB), Lipoprotein(a) (Lpa), Interleukin-6 (IL-6), and high-sensitivity CRP (HsCRP)) showed great promise in optimizing primary CV risk assessment and management for seemingly healthy individuals with or without subclinical atherosclerosis. The gene discussed is APOB; the disease is atherosclerosis.